Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average – Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.73 and traded as low as $0.72. Vaxart shares last traded at $0.74, with a volume of 1,361,347 shares traded.

Vaxart Price Performance

The company has a market capitalization of $168.72 million, a PE ratio of -1.81 and a beta of 0.62. The business has a 50-day moving average of $0.66 and a 200 day moving average of $0.73.

Institutional Investors Weigh In On Vaxart

A number of hedge funds have recently made changes to their positions in the company. Mesirow Financial Investment Management Inc. lifted its position in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after buying an additional 122,387 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after buying an additional 346,725 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Vaxart by 110.8% in the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 2,095,274 shares in the last quarter. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.